Zepbound Canada: Cost, Dosing, and How It Compares to Mounjaro and Wegovy

Updated October 5, 2026

In recent years, Canadians seeking tirzepatide for weight loss only had one option: an off-label prescription for Mounjaro, the diabetes brand of the medication. That changed in mid-2025, when Zepbound — the weight-management brand of tirzepatide — was approved by Health Canada.

The arrival of Zepbound in Canada follows a broader shift in how doctors view obesity. The Canadian Adult Obesity Clinical Practice Guidelines now frame obesity as a complex condition that warrants long-term medical management, rather than short-term lifestyle advice alone. Highly effective medications like Zepbound are now a central part of how long-term weight loss care is delivered in Canada.

This article covers what Zepbound is, how it compares to Mounjaro, Ozempic, and Wegovy, and what the Canadian label actually says about sleep apnea. We also break down Zepbound’s cost, dosing schedule, and side effects. 

What Is Zepbound?

Zepbound is a once-weekly injection used for long-term weight management. It is manufactured by Eli Lilly, and the active ingredient is tirzepatide — the same molecule sold under the brand name Mounjaro for type 2 diabetes.

What makes tirzepatide distinct from other weight loss injections is how it works. Drugs like Ozempic and Wegovy mimic a single gut hormone called GLP-1. Tirzepatide mimics two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This “dual-agonist” effect appears to produce greater weight loss than targeting GLP-1 alone.

In Canada, Zepbound is approved as a long-term treatment for adults with obesity (BMI ≥30), or those who are overweight (BMI ≥27) and living with at least one weight-related health condition (including hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease). Guidelines state that Zepbound should be prescribed alongside a reduced-calorie diet and increased physical activity.

How Does Zepbound Work for Weight Loss?

Zepbound mimics GLP-1 and GIP, which are two incretin hormones released by the intestine after meals. These hormones work on overlapping but distinct parts of the body’s appetite and energy regulation system. 

Activating the GLP-1 receptor is known to:

• Slow gastric emptying
• Reduce hunger signals in the brain
• Enhance insulin secretion

The added GIP receptor activation from Zepbound appears to amplify these effects, and may also influence how the body stores and uses fat.

In practice, Zepbound weight loss occurs in a similar way to other GLP-1 medications. Food stays in the stomach longer after meals, hunger between meals is reduced, and many people report a noticeable drop in the persistent background thoughts about food.

How Much Weight Can You Lose on Zepbound?

In clinical trials, adults on the highest dose of Zepbound lost an average of roughly 21% of their body weight over 72 weeks. This is the largest average weight loss reported for any prescription medication currently approved in Canada for chronic weight management.

Below is a brief summary of the main research trials done with Zepbound and the weight loss results achieved. 

SURMOUNT-1 Trial Results

The main evidence for Zepbound comes from SURMOUNT-1, a phase 3 randomized trial of 2,539 adults with obesity or overweight (without type 2 diabetes), treated with tirzepatide (the active ingredient of Zepbound). 

Over 72 weeks, average weight loss was:

• 5 mg dose: 15.0% of body weight
• 10 mg dose: 19.5% of body weight
• 15 mg dose: 20.9% of body weight
• Placebo: 3.1% of body weight

About 91% of participants on the 15 mg Zepbound dose lost at least 5% of their body weight, and more than half lost 20% or more.

Long-Term Results

A three-year follow-up analysis of patients enrolled in the SURMOUNT trial confirmed the weight loss from Zepbound was sustained over 176 weeks, with an average weight loss of 19.7% after three years on the 15 mg dose. This analysis also found that treatment significantly reduced the rate of progression from prediabetes to type 2 diabetes.

What Happens If You Stop Taking Zepbound?

As with all GLP-1-based medications, the results from Zepbound largely depend on staying on the medication. Observational and trial data suggest most of the weight is regained if treatment is stopped. This is why Zepbound (like Wegovy, Ozempic, and Mounjaro) is considered a long-term therapy.

Is Zepbound Available in Canada?

Health Canada approved Zepbound on May 13, 2025, and Eli Lilly launched the medication at Canadian pharmacies on July 9, 2025. It is a prescription-only medication, which means patients need to consult with a licensed Canadian healthcare provider to determine whether it’s an appropriate treatment option for them.

In Canada, Zepbound is sold exclusively as the KwikPen — a multi-dose prefilled pen containing four weekly doses. This is a different format from the single-dose auto-injector pens Zepbound launched with in the United States.

Zepbound vs Mounjaro

Zepbound and Mounjaro contain the exact same active ingredient (tirzepatide), at the same doses, delivered in similar pens. The shared active ingredient does not guarantee an identical response for every patient, and there is an important regulatory difference. 

Mounjaro is officially approved by Health Canada for type 2 diabetes, while Zepbound is approved for chronic weight management. Lilly markets them as separate brands so each can carry an indication-specific label, packaging, and patient support material.

In practice, Canadians with type 2 diabetes who want tirzepatide would typically be prescribed Mounjaro, while those pursuing weight loss without diabetes would be prescribed Zepbound.

What About “Off-Label” Mounjaro?

Before Zepbound’s approval, Canadians who wanted tirzepatide for weight loss relied on off-label prescriptions for Mounjaro. Off-label prescribing is a common and legal practice in Canada, where a licensed provider prescribes an approved medication for a use Health Canada has not specifically authorized. 

Zepbound’s approval gives weight-management patients an on-label option with the identical molecule. Coverage depends on the exact plan, indication and prior-authorization rules; a product being approved for weight management does not guarantee reimbursement. Lilly offers support and savings programs for eligible patients.

Zepbound vs Ozempic: Are They the Same?

Zepbound (tirzepatide) and Ozempic (semaglutide) are different molecules made by different manufacturers. They are often grouped together in conversation as “GLP-1s,” but this comparison is imprecise.

While there is some overlap between how Zepbound and Ozempic work, there are several important differences to be aware of, including:

• Active ingredient: Zepbound contains tirzepatide, while Ozempic contains semaglutide — two distinct molecules.
• Mechanism: Zepbound is a dual agonist that activates both GLP-1 and GIP receptors. Ozempic is a GLP-1 receptor agonist only.
• Manufacturer: Zepbound is made by Eli Lilly; Ozempic is made by Novo Nordisk.
• Canadian indication: Zepbound is approved for chronic weight management. Ozempic is approved only for type 2 diabetes, so any prescription for weight loss is off-label — the on-label semaglutide option for weight management in Canada is Wegovy.
• Weight loss outcomes: Average weight loss on tirzepatide has been greater than on semaglutide in head-to-head trial data.

In short, Zepbound and Ozempic are part of the same broader drug class, but they are not interchangeable. The medications have different molecules, different mechanisms, and different approved uses in Canada.

Zepbound vs Wegovy

The most relevant head-to-head comparison for Canadians considering Zepbound is against Wegovy, the branded version of semaglutide approved for weight management. 

Both are once-weekly GLP-1-based injectables approved by Health Canada for weight management. However, there are some important differences between the medications that patients should be aware of.

We cover the main differences between Zepbound and Wegovy below. But as always, you should speak with a doctor to get advice based on your personal situation before deciding which one might be right for you.

SURMOUNT-5: The Head-to-Head Trial

The SURMOUNT-5 trial compared Zepbound and Wegovy directly over 72 weeks in 751 adults with obesity or overweight, without diabetes. 

Here are the key findings:

• Average weight loss: 20.2% on Zepbound vs 13.7% on Wegovy (roughly 47% more weight loss from Zepbound).
• Participants who lost 15% of body weight or more: 64.6% on Zepbound vs 40.1% on Wegovy.
• Participants who lost 25% of body weight or more: 31.6% on Zepbound vs 16.1% on Wegovy.
• Discontinuation due to side effects: 2.7% on Zepbound vs 5.6% on Wegovy.

To summarize, Zepbound produced greater weight loss than Wegovy across every threshold measured, with fewer participants stopping the medication because of side effects.

Where Wegovy Still Has an Edge

Greater weight loss does not automatically make Zepbound the right choice for every person. 

Here are a few things that work in Wegovy’s favour:

• Cardiovascular outcome data: The SELECT trial demonstrated that Wegovy reduced the risk of major adverse cardiovascular events in adults with obesity and established heart disease. Zepbound does not yet have equivalent outcome data, though trials are ongoing.
• Longer track record in Canada: Wegovy has been prescribed in Canada for longer than Zepbound, meaning both doctors and patients have more real-world familiarity with how it performs outside a clinical trial setting.
• Insurance coverage. Compare the exact plan rules and pharmacy quotes for each product. Health Canada authorized Sevmia, a generic version of Wegovy, on June 29, 2026; authorization does not guarantee local stock or a particular out-of-pocket price.

Choosing Between Zepbound and Wegovy

There is no universally correct answer about whether Wegovy vs Zepbound is the best choice. 

The right fit always depends on an individual’s medical history, weight loss goals, susceptibility to side effects, cost, insurance coverage, and whether cardiovascular risk reduction is a specific treatment priority. In all cases, this decision should be made with a licensed healthcare provider who can review your full medical history and personal background.

Zepbound for Sleep Apnea: Does It Actually Work?

Health Canada authorized Zepbound on June 11, 2026 to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity (BMI at least 30), alongside reduced-calorie diet and increased physical activity. It does not replace PAP therapy when PAP is needed; changes to that treatment require the healthcare provider.

In the SURMOUNT-OSA trials, average breathing-event reductions after 52 weeks were about 25 per hour with tirzepatide versus 5 with placebo among adults not using PAP, and 29 versus 6 among adults using PAP. Remission or mild non-symptomatic OSA occurred in 42% versus 16% and 50% versus 14%, respectively. These are trial averages, not guaranteed outcomes.

How Much Does Zepbound Cost in Canada?

As checked October 5, 2026, Lilly Canada advertises Zepbound from $300 per month with its Savings Card for eligible patients. The estimate is based on a 28-day supply; exclusions apply, dispensing fees are extra, and pharmacy and insurance details affect the price. Ask for a current quote and check the exact provincial or private-plan criteria. 

Private plans may cover Zepbound with prior authorization, typically requiring a BMI of 30 or higher (or 27 with a documented weight-related comorbidity). Benefits Canada reports that weight-management drugs are expected to be a major driver of private drug plan costs in 2026, reflecting how rapidly this category is expanding.

Eli Lilly Canada offers a patient support program, which can help eligible patients navigate private insurance coverage and reduce out-of-pocket Zepbound costs in Canada.

Zepbound Dosing

Zepbound uses a gradual dose increase schedule to give the body time to adjust and minimize gastrointestinal side effects. 

Here is the standard schedule for Zepbound dosing:

• Weeks 1–4: 2.5 mg once weekly (initiation dose; not a maintenance dose)
• Weeks 5–8: 5 mg once weekly
• Further increases: 2.5 mg increments at intervals of at least 4 weeks, as needed for clinical response and tolerability
• Maximum dose: 15 mg once weekly

For weight management, maintenance doses are 5, 10 or 15 mg weekly; for OSA, 10 or 15 mg weekly. A missed dose may be taken within 96 hours; otherwise skip it and resume the regular day. Do not double doses. The slow increase exists because the most common side effects — nausea, diarrhea, constipation, vomiting — typically peak during dose increases. Most patients tolerate these increases better when they spend a full four weeks (or longer) at each level before moving up.

Zepbound Side Effects

As with other GLP-1 and GLP-1/GIP agonists, side effects of Zepbound are mostly gastrointestinal. 

The most commonly reported include:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain
• Decreased appetite
• Fatigue
• Injection-site reactions

Most Zepbound side effects are mild to moderate and tend to improve after a few weeks on a given dose. 

In SURMOUNT-1, discontinuation due to adverse events on the highest dose was around 6%, and the pattern of side effects was similar to what’s seen with other GLP-1-based weight loss treatments.

Tips for Managing Zepbound Side Effects

To reduce the likelihood of gastrointestinal discomfort from Zepbound, consider:

• Eating smaller and more frequent meals rather than large ones
• Avoiding greasy, fried, or heavily spiced foods (especially during dose increases)
• Staying well hydrated
• Eating slowly until you feel satisfied rather than full

These are the same strategies recommended for patients on Ozempic, Wegovy, and Mounjaro.

Serious Risks and Who Should Not Take Zepbound

More serious but less common risks from Zepbound include:

• Pancreatitis
• Gallbladder problems
• Kidney injury (usually linked to dehydration from vomiting or diarrhea)
• Severe allergic reactions

Zepbound carries a Canadian Serious Warnings and Precautions box for thyroid C-cell tumours based on rodent studies, and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Hypersensitivity to tirzepatide or an ingredient is another contraindication. Prior pancreatitis requires caution, while severe gastrointestinal disease including severe gastroparesis is not recommended; gallbladder disease requires assessment.

Zepbound is contraindicated during pregnancy and should be stopped at least one month before a planned pregnancy. Breastfeeding requires an individualized benefit-risk discussion. Do not combine it with another tirzepatide or GLP-1 medicine. Oral hormonal contraception needs a non-oral alternative or added barrier method for four weeks after starting and each dose increase. Tell anesthesia teams about treatment.

Frequently Asked Questions About Zepbound

Is Zepbound approved in Canada? 

Yes. Health Canada approved Zepbound on May 13, 2025, and it launched at Canadian pharmacies on July 9, 2025. It’s the first Health Canada–approved tirzepatide (the active ingredient of Zepbound and Mounjaro) specifically for chronic weight management.

What is Zepbound used for? 

In Canada, Zepbound is approved for chronic weight management in eligible adults, and for moderate-to-severe OSA in adults with obesity. For weight management, BMI criteria are at least 30, or 27 to under 30 with a weight-related condition.

Zepbound cost in Canada without insurance? 

Lilly Canada advertises a Savings Card price from $300 per 28-day supply for eligible patients, with exclusions and dispensing fees extra. The pharmacy cash price and amount after insurance vary.

How much is Zepbound in Canada with insurance? 

Private insurance plans that cover anti-obesity medications typically require prior authorization based on BMI and comorbidity criteria. Copays vary widely by plan. Public coverage depends on the province, indication and current formulary criteria.

Is Zepbound the same as Ozempic? 

No. Zepbound is tirzepatide (a dual GIP/GLP-1 agonist) made by Eli Lilly. Ozempic is semaglutide (a GLP-1 agonist only) made by Novo Nordisk. Different molecules, different manufacturers, different mechanisms.

Is Zepbound the same as Mounjaro? 

Yes and no. Both contain tirzepatide at the same doses, but Mounjaro is approved in Canada for type 2 diabetes, while Zepbound is approved for chronic weight management.

How much weight can you lose on Zepbound? 

In the SURMOUNT-1 trial, adults without type 2 diabetes on the 15 mg dose of tirzepatide lost an average of about 20.9% of their body weight over 72 weeks, with sustained results confirmed at three years.

Zepbound Canada: Final Thoughts

Zepbound is one of the most effective weight loss medications available in Canada. But effectiveness alone doesn’t determine whether it’s the right fit for an individual. 

Medical history, current medications, BMI criteria, insurance coverage, cost, and side effects all factor into the decision about whether Zepbound is a suitable weight loss treatment. It’s also important to compare Zepbound against alternatives, like Wegovy or Contrave, which work through entirely different mechanisms.

A healthcare provider can help you evaluate whether Zepbound might be a suitable medication to support your weight loss goals. If Zepbound is appropriate, they can also guide you through starting the medication and monitoring long-term effectiveness.

Walk In connects eligible patients in selected Metro Vancouver communities with physicians for phone or video consultations when available. The physician assesses treatment suitability; appointments do not guarantee a prescription or coverage.

Speak With a Virtual Doctor About Weight Loss Treatment